T2 Biosystems, Inc.

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
5.05 ^USD	-0.59%		-5.78%	-19.52%

Jun. 25	T2 Biosystems Signs Exclusive Distribution Deal for Hong Kong, Macau	MT
Jun. 25	T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor	CI

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

November 07, 2022 at 09:01 am EST

T2 Biosystems, Inc. announced On November 1, 2022, Alec Barclay notified T2 Biosystems, Inc. of his resignation as Chief Operations Officer of the Company, effective as of November 30, 2022.

Latest news about T2 Biosystems, Inc.

T2 Biosystems Signs Exclusive Distribution Deal for Hong Kong, Macau	Jun. 25	MT
T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor	Jun. 25	CI
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	May. 15	MT
T2 Biosystems Shares Rise After CRG Servicing Ups Stake	May. 15	MT
Top Midday Gainers	May. 15	MT
T2 Biosystems, Inc. announced that it expects to receive $7.999677 million in funding	May. 13	CI
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	May. 07	CI
North American Morning Briefing : Stock Futures Muted After Rally Fueled by Rate-Cut Hopes	May. 07	DJ
T2 Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M	May. 06	MT
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024	May. 06	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Middle East Distributor	May. 06	CI
Transcript : T2 Biosystems, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating	Apr. 29	MT
Top Premarket Decliners	Apr. 23	MT
T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
Transcript : T2 Biosystems, Inc. - Special Call	Mar. 20
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Feb. 12	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	Feb. 12	MT

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.05 USD

Average target price

3 USD

Spread / Average Target

-40.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
T2 BIOSYSTEMS, INC.	-19.52%	86.18M
THERMO FISHER SCIENTIFIC	+0.91%	204B
DANAHER CORPORATION	+3.74%	178B
INTUITIVE SURGICAL, INC.	+28.89%	154B
BOSTON SCIENTIFIC CORPORATION	+31.66%	112B
SIEMENS HEALTHINEERS AG	+1.37%	64.16B
EDWARDS LIFESCIENCES CORPORATION	+19.45%	54.88B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-2.27%	46.69B
AGILENT TECHNOLOGIES, INC.	-9.28%	36.8B
GE HEALTHCARE TECHNOLOGIES INC.	-0.10%	35.26B

Other Advanced Medical Equipment & Technology